ReviewScience (New York, N.Y.)2025
From reactive to proactive: Continuous protein monitoring for preventive health care.
Review in Science (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Interrelations of work with health and wellbeing on a 50+ year old workforce assessed using longitudinal self-reports and actigraphy.Scientific reports · 2026Article
- Predicting health and disease: a conceptual framework for AI in preventive and precision medicine.BMJ health & care informatics · 2026Review
- A time bridge for obesity care: protein monitoring adds a timing layer to the EASO pathway while preserving the Lancet Commission definition.International journal of obesity (2005) · 2026Review
- Single-molecule readout of reversible nanoswitches enables continuous monitoring of low biomarker concentrations.Nature communications · 2026Article
- Reversible Sandwich-Based Particle Nanoswitch for Continuous Protein Monitoring at Picomolar Concentrations with Automated Calibration.Angewandte Chemie (International ed. in English) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Continuous biomarker monitoring is revolutionizing chronic disease management, with glucose monitoring for diabetes as the primary example. Given the success of this approach, a transition to continuous protein monitoring (CPM, a real-time, implantable or wearable technology) could similarly advance precision medicine. In this work, we review state-of-the-art CPM platforms and their prospective clinical impact across both chronic disorders-metabolic, cardiovascular, autoimmune, and neurodegenerative-and acute crises, such as sepsis and transplant dysfunction. We also highlight remaining barriers to widespread adoption, including sensor stability, robust machine learning models for live interpretation, and responsible data handling for patient privacy. With continued engineering and clinical validation, emerging biosensor technologies could transform disease management, facilitating earlier interventions and individualizing treatment strategies, ultimately improving patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.